集中带量采购和医保谈判政策对表皮生长因子受体酪氨酸激酶抑制剂药品采购的影响——以吉非替尼和奥希替尼为例
The Impact of Volume-based Procurement and Government Reimbursement Negotiation Policies on EGFR-TKI Drug Procurement:A Case Study of Gefitinib and Osimertinib
易洪彬 1石丰豪 1蒯丽萍 2徐冬艳 2韩晟1
作者信息
- 1. 北京大学医药管理国际研究中心,北京 100191
- 2. 中国药学会科技开发中心,北京 100022
- 折叠
摘要
目的 评估集中带量采购和医保谈判政策对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)药品采购的影响,为集中带量采购和医保谈判政策的完善与推进提供实证参考依据.方法 梳理集中带量采购和医保谈判中涉及的EGFR-TKI 药品,遴选合适的EGFR-TKI药品,使用间断时间序列模型评估集中带量采购和医保谈判政策对其限定日费用(DDDc)、使用强度(DDDs)和采购金额的影响.结果 集中带量采购政策实施后,吉非替尼的 DDDc 和采购金额显著下降(P<0.05),DDDs 呈下降趋势(P<0.05).医保谈判政策实施后,奥希替尼药品的 DDDc 显著下降(P<0.005),采购金额显著上升(P<0.05),DDDs的上升趋势增大(P<0.05).结论 集中带量采购和医保谈判政策对EGFR-TKI药品采购的影响显著,这些影响有助于减轻患者经济负担,满足其临床用药需求.
Abstract
Objective To evaluate the impact of volume-based procurement and government reimbursement negotiation policies on EGFR-TKI drugs procurement,and to provide empirical reference for the improvement and promotion of volume-based procurement and government reimbursement negotiation.Methods The EGFR-TKI drugs involved in volume-based procurement and government reimbursement negotiation were sorted out,and the appropriate EGFR-TKI drugs were selected.ITS model was used to evaluate the impacts of volume-based procurement and government reimbursement negotiation on DDDc,DDDs and procurement spending.Results After the implementation of the centralized procurement policy,the DDDc and procurement amount of gefitinib decreased significantly(P<0.05),and the DDDs showed a downward trend(P<0.05).After the implementation of the medical insurance negotiation policy,the DDDc of ohitinib drugs decreased significantly(P<0.05),the purchase amount increased significantly(P<0.05),and the upward trend of DDDs increased(P<0.05).Conclusion Centralized procurement and medical insurance negotiation policies have significant effects on EGFR-TKI drug procurement,which can help to reduce patients'economic burden and meet their clinical drug needs.
关键词
集中带量采购/医保谈判/表皮生长因子受体酪氨酸激酶抑制剂/间断时间序列分析Key words
Volume-based procurement/Government reimbursement negotiation/EGFR-TKI/Interrupted time series analysis引用本文复制引用
基金项目
国家医疗保障局(医药服务管理司)立项课题(第2022020号)
出版年
2024
国家科技期刊平台
NSTL
万方数据